Pfizer Inc. (PFE)
Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Pfizer (PFE) closed the most recent trading day at $26.86, moving 1.61% from the previous trading session.
Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study
U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin disease met the main goal in a mid-stage study.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
China approves Pfizer GLP-1 drug for weight management
China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting competition in a market analysts expect to be worth billions in coming years.
Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund
A federal judge on Thursday awarded Pfizer $29 million to resolve a dispute with the U.S. Securities and Exchange Commission stemming from the regulator's 2013 insider trading settlement with billionaire Steven A. Cohen's former hedge fund SAC Capital Management.
Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations?
PFE faces falling COVID sales, looming patent cliffs and IRA pressure. It is betting on cost cuts, new launches and pipeline rebuilds to revive growth.
Pfizer's Portfolio Renewal In Progress - High Yields For The Patient
Pfizer's portfolio renewal is in progress, with new launches and acquisitions driving +14.6% YoY growth in new product revenues, though legacy drug expiries may pressure intermediate-term sales. These developments lend credence to their frenzied M&A/licensing activities despite the potential debt risks, given the reasonable, estimated net interest coverage ratio of 6.91x. Their R&D efforts are still reasonable at ~16.6% of their top lines in FY2025, near their 5Y pre-pandemic averages of ~16.3%, with it presenting the sector's capital-intensive R&D/M&A thesis.
Pfizer's Quiet Cash Comeback
Pfizer delivers a 75.81% gross margin and 41.05% EBITDA margin, dramatically outperforming sector medians of 59.35% and 10.40%. Management targets $1.3 billion in net cost savings by 2026, reinforcing structural margin durability despite revenue pressure. Trailing operating cash flow reached $13.08 billion, fully covering $9.8 billion in dividends with a 6.22% yield.
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?
Pfizer's PFE stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January.
Pfizer Adds Sciwind As China Partner For New Weight Loss Drug
In the latest China pharmaceutical industry collaboration pact with a global drug leader, Hangzhou Sciwind Biosciences said today it had reached an agreement with Pfizer China to team up on the commercialization of a new-generation weight management and diabetes treatment, in a deal worth up to $495 million for the Chinese company.
